- Home
- Products
Imjudo (Tremelimumab)
Imjudo (Tremelimumab)
- Medicine Name: Imjudo
- Generic Name: Tremelimumab
- Dosage Form & Strength: Injection – 25 mg/1.25 mL and 300 mg/15 mL (20 mg/mL)
- Manufactured By: AstraZeneca Pharmaceuticals LP
Imjudo is a CTLA-4 immune checkpoint inhibitor used in combination therapy to treat adult patients diagnosed with:
- Unresectable hepatocellular carcinoma (uHCC) – alongside Imfinzi (durvalumab)
- Metastatic non-small cell lung cancer (NSCLC) – alongside Imfinzi and platinum-based chemotherapy
(for patients without EGFR or ALK genomic tumor alterations)
Recommended Dosage:
- uHCC (≥30 kg): Imjudo 300 mg once with Imfinzi 1,500 mg (Cycle 1 Day 1); continue Imfinzi monotherapy every 28 days
- uHCC (<30 kg): Imjudo 4 mg/kg once with Imfinzi 20 mg/kg; then Imfinzi alone every 28 days
- NSCLC (≥30 kg): Imjudo 75 mg every 21 days (4 cycles) with Imfinzi 1,500 mg + chemo; followed by maintenance Imfinzi + pemetrexed; 5th Imjudo dose with 6th Imfinzi at week 16
- NSCLC (<30 kg): Imjudo 1 mg/kg + Imfinzi 20 mg/kg with platinum-based chemo for 4 cycles; continue with maintenance and a 5th Imjudo dose as above
Infuse over 60 minutes. Do not administer subcutaneously.
- Endocrinopathies: Risk of immune-mediated hypophysitis, which may cause hormonal imbalance. Start hormone replacement if necessary.
- Hyperglycemia: Monitor for elevated blood glucose; manage with insulin if needed.
- Skin Reactions: Risk of dermatitis and immune-mediated rash. Treat mild cases with emollients or topical corticosteroids.
- Infusion Reactions: Can occur during or after infusion. Monitor and interrupt or discontinue treatment depending on severity.
- Pregnancy Risk: May cause fetal harm. Use effective contraception during and for 90 days after the last dose.
To Import Imjudo into India, you will need:
- A valid prescription from a certified oncologist
- Diagnostic reports confirming indication
- Government-issued patient ID
Availability in India:
Imjudo is available through Global Rare Meds under the Named Patient Import Program. We support legal access in cities including Mumbai, Delhi, Chennai, Hyderabad, Bengaluru, Pune, Kolkata, Ahmedabad, and more.
📧 info@globalraremeds.com
📞 +91-99675 15602 (Call or WhatsApp)
Global Rare Meds sources Imjudo (Tremelimumab) directly from trusted suppliers in the USA, Canada, Europe, and Australia, with delivery fulfilled via our licensed distribution center in Ambernath, Thane District.
We ensure:
- Verified cold chain delivery
- Regulatory compliance with Indian import laws
- Fast processing with valid prescription
- Quality assurance and pharmacist-checked shipments
Q: What is the generic name for Imjudo®?
A: Tremelimumab
Q: Who manufactures Imjudo®?
A: AstraZeneca Pharmaceuticals LP
Q: What is Imjudo® used for?
A: It is used with Imfinzi for treating unresectable liver cancer (uHCC) and metastatic NSCLC in adult patients.
Q: Is Imjudo® approved by the FDA?
A: Yes, approved by the FDA on October 21, 2022.
Q: What are the available strengths of Imjudo®?
A: 25 mg/1.25 mL and 300 mg/15 mL (20 mg/mL) vials
Q: What are the most common side effects?
A:
In uHCC: rash, fatigue, diarrhea, abdominal pain, pruritus, musculoskeletal pain
In NSCLC: nausea, decreased appetite, fatigue, diarrhea, skin rash, and joint pain
Q: What are the storage conditions?
A: Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in original packaging. Do not freeze or shake.
Q: How much does Imjudo® cost in India?
A: Pricing varies based on dose and global supply. Contact info@globalraremeds.com or +91-99675 15602 for current quotes.
Q: Can I buy Imjudo® online in India?
A: Yes. Global Rare Meds facilitates the legal and safe import of Imjudo with a valid
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
